Adult T-cell leukemia-lymphoma · 3 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Alemtuzumab monotherapy Variant #01 | — | R 132 218 | 7d | ~15.0 mo | — | ~66 | ~R 8 726 355 PFS proxy · indirect | — |
Lenalidomide monotherapy N/A - secondary systemic drug | — | R 6 361 | 90d | ~39.0 mo | ~113.8 mo | ~14 | ~R 89 057 PFS proxy · indirect | 10 |
Valemetostat monotherapy Variant #01 Partial | — | — | 28d | — | — | — | — | — |
3 of 3 regimens shown